Adebrelimab

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) 抑制 SK-BR-3 和 AU565 细胞的增殖、迁移、侵袭[1]。 Adebrelimab（SHR-1316；0.1-1mg/mL；48 小时）下调 PD-L1、p-PI3K、p-AKT 的表达并上调 FOXO1 的表达[1]。SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursPromoted cell apoptosis.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL24 hoursDecreased the migration rate of SK-BR -3 and AU565 cells.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursDownregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1. Cell Viability Assay[1] Cell Line: SK-BR-3 and AU565 cells Concentration: 0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL Incubation Time: 48 hours Result: The viability of SK-BR-3 and AU565 cells decreased gradually. Apoptosis Analysis[1] Cell Line: SK-BR-3 and AU565 cells Concentration: 0.1 mg/mL, 1 mg/mL Incubation Time: 48 hours Result: Promoted cell apoptosis. Cell Migration Assay [1] Cell Line: SK-BR-3 and AU565 cells Concentration: 0.1 mg/mL, 1 mg/mL Incubation Time: 48 hours Result: Decreased the migration rate of SK-BR -3 and AU565 cells. Western Blot Analysis[1] Cell Line: SK-BR-3 and AU565 cells Concentration: 0.1 mg/mL, 1 mg/mL Incubation Time: 48 hours Result: Downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.

Adebrelimab（SHR-1316；200 μg；每周 3 次；持续 21 天）显示出对肿瘤生长的抑制作用[1]。 Animal Model: Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells[1] Dosage: 200 μg Administration: Three times a week; for 21 days Result: Significantly inhibited tumor growth.

[1]. Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.

[2]. Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.